Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms VIDA
Sponsors Merck Sharp & Dohme Corp.

01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
10 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
01 Apr 2011 Planned end date changed from May 2012 to Jun 2013 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com